Drug Discovery

Aerogen Pharma, Lyomark Pharma to develop inhaled surfactant

Aerogen Pharma and Lyomark Pharma have partnered to develop a clinically superior treatment for Respiratory Distress Syndrome (RDS), a life-threatening condition of preterm infants associated with long-term lung health issues in survivors.

Report expects global cryotherapy market to cross $4bn by 2024

A new report from Persistence Market Research expects worldwide cryotherapy market to exceed $4bn by 2024.

bluebird bio, TC BioPharm to develop Gamma Delta CAR T cell product candidates for cancer immunotherapy

bluebird bio and Scottish immunotherapy company TC BioPharm have partnered and signed a license agreement on gamma delta CAR T cells.

Gilead Sciences to acquire Cell Design Labs in $567m deal

Gilead Sciences and its cell therapy subsidiary Kite have agreed to acquire Cell Design Labs, a biotherapeutics company that discovers and develops cell-based therapies, for about $567m.

Fate Therapeutics, University of California San Diego launch CAR NK Cancer immunotherapy collaboration

Fate Therapeutics has partnered with the University of California San Diego to develop off-the-shelf, chimeric antigen receptor (CAR)-targeted natural killer (NK) cell cancer immunotherapies.

Researchers show aspirin added to cancer drug improves effectiveness

Adding aspirin to some existing cancer drugs could increase their effectiveness against a group of tumours resistant to treatment, new research has shown.

Blue Oak, PsychoGenics enter into drug discovery partnership

Blue Oak Pharmaceuticals and PGI Drug Discovery (PsychoGenics) have entered into a partnership to discover and optimize novel treatments for brain disorders and psychiatric conditions.

Astellas Pharma acquires Mitobridge for $225m

Astellas Pharma has exercised its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement governing their research and development (R&D) collaboration focused on discovering and developing novel drugs that target mitochondrial function.

I-Mab Biopharma partners with MorphoSys on cancer investigational medicine

I-Mab Biopharma and MorphoSys have entered into an exclusive regional licensing agreement to develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao.